Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Acrivon Therapeutics, Inc. (ACRV) has shared an update.
On April 24, 2024, the Company announced promising clinical trial results for ACR-368, showing a 50% response rate in patients with specific cancer markers, and stability in other patients when combined with a low-dose drug. Alongside this, the Company’s virtual R&D event highlighted their financial health, with a substantial cash balance indicating funding secured until the latter part of 2026. This combination of scientific advancement and strong financial positioning suggests a positive trajectory for the Company’s future endeavors in cancer treatment.
For detailed information about ACRV stock, go to TipRanks’ Stock Analysis page.
